The company has aspirations for a combined molecular/immunoassay platform, but plans to go to market with a 22-target real-time PCR-enabled syndromic panel.
The Alabama-based firm has grown its infectious disease testing menu for the BD Max system to six CE-marked tests identifying bacteria, viruses, or fungi.
The companies will work together to secure US approval for SpeeDx's antibiotic-resistant Mycoplasma genitalium assay.
The new panel is able to detect up to 130 pathogens that cause severe abdominal infections, such as appendicitis and acute pancreatitis.
The funds will be used in part to support commercial activities related to the firm's ThermaStop and ThermaGo PCR additive reagents.
Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.
An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.
At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.
In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.